LENZ

MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. Since receiving U.S. Food and Drug Administration (FDA) approval in July 2025, LENZ has moved rapidly to expand global access

SCHEDULE 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

S-8 - LENZ Therapeutics, Inc. (0001815776) (Filer)

10-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals Compelling real-world performance of VIZZ, combined with broad prescriber uptake and encouraging early refill trends, reinforces confidence in its best-in-class profile and establishment of a durable new category Management to host conference call today, March 24, 2026, at 8:30am EDT SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ)

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, March 24, 2026, at 8:30 a.m. EDT to report its fourth quarter and full year 2025 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 5138264. The live webcast can be accessed here and on the LENZ Therapeutics web

MAA submission to the European Medicines Agency represents a key regulatory milestone in LENZ's strategy to expand global access to VIZZ Submission of MAA in Europe results in the fifth ex-U.S. regulatory submission for VIZZ SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review and approval of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. If approved, the EMA's positive opinion would serve as a foundational step toward making VIZZ availab

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care ConferenceDate: March 2, 2026Location: Boston, MAFormat: Fireside chat at 9:50am ET (live audio webcast) and 1x1 investor meetings Leerink Partners 2026 Global Healthcare Conference Date: March 10, 2026Location: Miami, FLFormat: Fireside chat at 10:00am ET (live

SCHEDULE 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

SCHEDULE 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The "Make it VIZZable" campaign features SJP enjoying the everyday convenience of clear near vision provided by using the VIZZ eye drops. VIZZ is available nationwide by prescription through eye doctors; visit VIZZ.com to learn more and to find a local provider offering a free sample SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), today announced the launch of "Make it VIZZable", the VIZZ consumer campaign with award-winning actor, producer and publisher, Sarah Jessica Parker ("SJP") as a brand ambassa

8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025 Over 6,500 unique ECPs prescribed VIZZ; more than 55% have prescribed multiple times in Q4 2025 SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported certain preliminary unaudited financial results fo

4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lunatus Marketing & Consulting FZCO ("Lunatus") today announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. Lunatus is an independent pharmaceutical company specialized in the commercialization of pharmaceutical products in the Middle East. Under the terms of

8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) for the review and approval of VIZZTM, for the treatment of presbyopia in adults in South Korea. This represents the first submission for approval under the exclusive license and commercialization agreement signed in May 2025 for South Korea and certain countries in Southeast Asia. The NDA submission was supported by positive data from three randomized, double-masked, controlled Phase 3 studies (CLARITY tri

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference Date: December 2, 2025Location: New York City, NYFormat: Fireside chat at 3:30pm ET (live audio webcast) and 1x1 investor meetings 8th Annual Evercore Healthcare ConferenceDate: December 3, 2025Location: Coral Gables, FLFormat: Fireside chat at 1: